Genetic studies are becoming an important component of clinical research. For instance, in the case of stroke studies, genetic markers might predict tendency to hemorrhage after various treatments. Genetic markers may point to expression of proteins. Based on these protein expressions, we may be able to develop a diagnostic profile to analyze ischemic damage to assist in determining whether urgent treatment is indicated. Additionally these markers may provide insight into the role of inflammation and accompanying immune response in strokes. By pursuing novel genetic studies, we can seek out supportive technology for our other SPOTRIAS goals.
Our specific aims are to: 1. Collaborate with other SPOTRIAS sites by providing blood and other human tissue as needed. 2. Continue genomics-based clinical research on acute stroke patients by harvesting and banking genomic DNA samples of patients enrolled in the acute stroke trials. 3. Research immune response in cerebrovascular disease searching for serum and cell markers of clinical outcome. The genetic revolution, typified by the latest findings of the genes associated with heart disease and diabetes, highlights inflammation-related genes as playing a major role in the analysis of vascular diseases. In recent years, there has been growing interest in inflammation in the setting of stroke and trials of immune treatments to improve clinical outcome. However, there remains a critical gap in our knowledge base in that the role of inflammation with its closely-related immune responses in determining stroke outcome is still unclear. The immune response associated with favorable early clinical outcome in Acute Ischemic Stroke (AIS) patients is unknown. Likewise, the influence on the degree of brain injury following AIS has not been systematically examined. In this core, we seek to facilitate the banking of blood samples with the SPOTRIAS repositories, while initiating the search for viable genetic and immune response markers that influence outcomes of stroke.
|Cai, Chunyan; Rahbar, Mohammad H; Hossain, Md Monir et al. (2017) A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research. Contemp Clin Trials Commun 7:11-17|
|Barreto, Andrew D; Ford, Gary A; Shen, Loren et al. (2017) Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke 48:1608-1616|
|Lyden, Patrick; Hemmen, Thomas; Grotta, James et al. (2016) Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). Stroke 47:2888-2895|
|Ifejika, Nneka Lotea; Noser, Elizabeth Anne; Grotta, James C et al. (2016) Swipe out Stroke: Feasibility and efficacy of using a smart-phone based mobile application to improve compliance with weight loss in obese minority stroke patients and their carers. Int J Stroke 11:593-603|
|McDonald, Mark M; Wetzel, Jeremy; Fraser, Stuart et al. (2016) Thrombelastography does not predict clinical response to rtPA for acute ischemic stroke. J Thromb Thrombolysis 41:505-10|
|Vahidy, F S; Rahbar, M H; Lal, A P et al. (2015) Patient refusal of thrombolytic therapy for suspected acute ischemic stroke. Int J Stroke 10:882-6|
|Ifejika, Nneka L; Vahidy, Farhaan; Aramburo-Maldonado, Linda A et al. (2015) Acute Intravenous Tissue Plasminogen Activator Therapy does not Impact Community Discharge after Inpatient Rehabilitation. Int J Neurorehabil 2:|
|Schlick, Konrad H; Hemmen, Thomas M; Lyden, Patrick D (2015) Seizures and Meperidine: Overstated and Underutilized. Ther Hypothermia Temp Manag 5:223-7|
|Huang, Richard S P; McDonald, Mark M; Wetzel, Jeremy S et al. (2015) Clot Strength as Measured by Thrombelastography Correlates with Platelet Reactivity in Stroke Patients. Ann Clin Lab Sci 45:301-7|
|Elliott, Andrea; Wetzel, Jeremy; Roper, Tiffany et al. (2015) Thromboelastography in patients with acute ischemic stroke. Int J Stroke 10:194-201|
Showing the most recent 10 out of 71 publications